Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that its wholly owned unit, Shanghai Zhaohui Pharmaceutical Company Limited, has received National Medical Products Administration (NMPA) approval for the registration of Dobutamine Hydrochloride Injection.

The product, classified as a chemical Class 3 drug, is indicated for short-term supportive treatment of heart failure stemming from reduced myocardial contractility, including low cardiac output syndrome following open-heart surgery. The approved specification is 5 ml: 100 mg (calculated as C₁₈H₂₃NO₃).

R&D expenditure on the project totaled approximately RMB5.09 million as of June 2026. According to IQVIA CHPA data, mainland China sales of comparable Dobutamine Hydrochloride Injections reached about RMB79.00 million in 2025, underscoring existing market demand.

Management expects the newly approved product to broaden the Group’s cardiovascular portfolio. However, future sales will depend on factors such as market competition, clinical adoption rates, and distribution channels, and thus remain subject to uncertainty.